Related Experiment Video
Updated: Jul 1, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Endocannabinoids in liver disease and hepatic encephalopathy
Iddo Magen1, Yosefa Avraham, Elliot Berry
1Department of Nutrition and Metabolism, Hebrew University Medical Faculty, Ein Kerem campus, Jerusalem 91120, Isreal. iddo.magen@mail.huji.ac.il
Abstract:
Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinically there may be progression to portal-hypertension and porto-systemic encephalopathy. Pioneering research from the laboratory of Kunos at NIH has stressed the importance of endocannabinoids (ECs) as mediators of some of the pathological processes in chronic liver disease. The present review summarizes the literature on the association between ECs and liver disease, as well as the therapeutic potential of ECs and exogenous cannabinoids in liver disease with emphasis on hepatic encephalopathy.
More Related Videos
14:25Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
Published on: September 21, 2019
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Related Concept Videos
Hepatic Encephalopathy
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Encephalitis ll: Pathophysiology
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids